Advertisement

PharmacoEconomics

, Volume 28, Issue 4, pp 323–344 | Cite as

Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

  • Jeroen P. JansenEmail author
  • Sabine Gaugris
  • Ernest H. Choy
  • Andrew Ostor
  • Julian T. Nash
  • Wiro Stam
Original Research Article

Abstract

Objective: To evaluate the cost effectiveness of etoricoxib (90mg/day) relative to celecoxib (200 or 400mg/day), and the non-selective NSAIDs naproxen (1000mg/day) and diclofenac (150 mg/day) in the initial treatment of ankylosing spondylitis (AS) from the UK NHS perspective.

Methods: A Bayesian cost-effectiveness model was developed to estimate the costs and benefits associated with initiating AS treatment with etoricoxib, celecoxib, diclofenac or naproxen. Efficacy, safety and medical resource and cost data were obtained from the literature. The obtained efficacy estimates were synthesized with a mixed treatment comparison meta-analysis. Treatment benefit and degree of disease activity, as reflected with Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, were related to QALYs and AS-specific costs (related to BASDAI). Other cost outcomes related to drug acquisition, and gastrointestinal and cardiovascular safety. Uncertainty in the source data was translated into uncertainty in cost-effectiveness estimates and therefore decision uncertainty. Costs and outcomes were discounted at 3.5% per annum.

Results: There was a >98% probability that treatment with etoricoxib results in greater QALYs than the other interventions. Over a 30-year time horizon, starting AS treatment with etoricoxib was associated with about 0.4 more QALYs than the other interventions. At 2 years there was a 77% probability that etoricoxib had the lowest cost. This increased to >99% at 30 years. Etoricoxib is expected to save £13 620 (year 2007 values) relative to celecoxib (200/400 mg), £9957 relative to diclofenac and d9863 relative to naproxen. For a willingness-to-pay ceiling ratio of £20 000 per QALY, there was a >97% probability that etoricoxib was the most cost-effective treatment. Additional analysis with different assumptions, including celecoxib 200 mg, and ignoring cost-offsets associated with improvements in disease activity, supported these findings.

Conclusions: This economic evaluation suggests that, from the UK NHS perspective, etoricoxib is the most cost-effective initial NSAID treatment for AS patients.

Keywords

Ankylose Spondylitis Celecoxib Naproxen Etoricoxib Bath Ankylose Spondylitis Disease Activity Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was funded by Merck & Co., Inc. At the time of the study Sabine Gaugris was an employee of Merck & Co., Inc. Jeroen Jansen and Wiro Stam have received payment from Merck & Co., Inc. for consultancy work. Ernest Choy has received honoraria and grants from Merck & Co., Inc. Andrew Ostor and Julian Nash have received honoraria from Merck & Co., Inc. for delivering lectures.

References

  1. 1.
    Gossec L, van der Heijde D, Melian A, et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 2005; 64: 1563–7PubMedCrossRefGoogle Scholar
  2. 2.
    Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005; 64: 1431–5PubMedCrossRefGoogle Scholar
  3. 3.
    Braun J, Bollow M, Remlinger G, et al. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58–67PubMedCrossRefGoogle Scholar
  4. 4.
    Clarke AK, O’Hea J, Irons K, et al., editors. Guidebook for patients: a positive response to ankylosing spondylitis. Answers and practical advice. Bath: Royal National Hospital for Rheumatic Diseases and The National Ankylosing Spondylitis Society, 2007 Mar [online]. Available from URL: http://www.nass.co.uk/public/zips/NassBook.pdf [Accessed 2008 Apr 1]Google Scholar
  5. 5.
    Arthritis Research Campaign. Arthritis: the big picture. Chesterfield: ARC, 2002Google Scholar
  6. 6.
    Boonen A, van der Heijde D, Landewe R. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003; 62: 732–40PubMedCrossRefGoogle Scholar
  7. 7.
    Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology 2004; 43: 1158–66PubMedCrossRefGoogle Scholar
  8. 8.
    Sieper J, Braun J. New treatment options in ankylosing spondylitis: a role for anti-TNFa therapy. Ann Rheum Dis 2001; 60: iii 58–61Google Scholar
  9. 9.
    Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817–24PubMedCrossRefGoogle Scholar
  10. 10.
    Zochling J, van der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006; 65: 423–32PubMedCrossRefGoogle Scholar
  11. 11.
    Keat A, Barkham N, Bhalla A, et al., BSR Standards, Guidelines and Audit Working group. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis: report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) 2005; 44: 939–47CrossRefGoogle Scholar
  12. 12.
    Ramey DR, Watson JD, Yu CB, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21: 715–22PubMedCrossRefGoogle Scholar
  13. 13.
    van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52: 1205–15PubMedCrossRefGoogle Scholar
  14. 14.
    Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised double-blind controlled study. Ann Rheum Dis 2008; 67 (3): 323–9PubMedCrossRefGoogle Scholar
  15. 15.
    Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase- 2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003; 17: 201–10PubMedCrossRefGoogle Scholar
  16. 16.
    Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98: 1725–33PubMedCrossRefGoogle Scholar
  17. 17.
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sep 13; 284 (10): 1247–55PubMedCrossRefGoogle Scholar
  18. 18.
    Jenkins JK, Seligman PJ. FDA decision memo-analysis and recommendations for agency action-COX-2 selective and non-selective NSAIDs [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106201.pdf [Accessed 2005 May 1]
  19. 19.
    Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771–81PubMedCrossRefGoogle Scholar
  20. 20.
    Cooper NJ, Sutton AJ, Abrams KR. Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for Caesarean section. Stat Methods Med Res 2002; 11: 491–512PubMedCrossRefGoogle Scholar
  21. 21.
    Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993 Oct-Dec; 13 (4): 322–38PubMedCrossRefGoogle Scholar
  22. 22.
    Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21 (12): 2281–5PubMedGoogle Scholar
  23. 23.
    Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21 (12): 2286–91PubMedGoogle Scholar
  24. 24.
    Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford) 2007; 46: 1338–44CrossRefGoogle Scholar
  25. 25.
    Barkhuizen A, Steinfeld S, Robbins J, et al. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 2006; 33: 1805–12PubMedGoogle Scholar
  26. 26.
    Dougados M, Behier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44: 180–5PubMedCrossRefGoogle Scholar
  27. 27.
    Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105–24PubMedCrossRefGoogle Scholar
  28. 28.
    Jansen JP, Crawford B, Bergman G, et al. Bayesian metaanalysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008; 11: 956–64PubMedCrossRefGoogle Scholar
  29. 29.
    Boonen A, van der Heijde D, Stevens JL, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006; 65: 201–8PubMedCrossRefGoogle Scholar
  30. 30.
    Taylor AL, Balakrishnan C, Calin A. Reference percentile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 1998; 41: 1119–25PubMedCrossRefGoogle Scholar
  31. 31.
    Botteman MF, Hay JW, Luo MP, et al. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford) 2007; 46: 1320–8CrossRefGoogle Scholar
  32. 32.
    Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a fiveyear observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006; 4: 600–6CrossRefGoogle Scholar
  33. 33.
    Laine L, Curtis SP, Cryer B, et al., for the MEDAL Steering Committee. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term(MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465–73PubMedCrossRefGoogle Scholar
  34. 34.
    Moore RA, Phillips CJP, Hunsche E, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 2004; 22 (10): 643–60PubMedCrossRefGoogle Scholar
  35. 35.
    Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment of arthritis. Am J Med 1998; 84: 315–22Google Scholar
  36. 36.
    Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990; 66: 639–46PubMedCrossRefGoogle Scholar
  37. 37.
    Singh G, Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective. 1997: arthritis, rheumatism, and aging medical information system. J Rheum 1998; 51: 8–16Google Scholar
  38. 38.
    de Pouvourville G. The economic consequences of NSAIDinduced gastropathy: the French context. Scan J Rheumatol 1992; 96: 49–53CrossRefGoogle Scholar
  39. 39.
    Jönsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Tech Assess Health Care 1992; 8: 234–44CrossRefGoogle Scholar
  40. 40.
    Gabriel SE, Matteson EL. Economic and quality of life impact of NSAIDs in rheumatoid arthritis: a conceptual framework and selected literature review. Pharmacoeconomics 1995; 8 (6): 479–90PubMedCrossRefGoogle Scholar
  41. 41.
    Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 1996; 11: 461–9PubMedCrossRefGoogle Scholar
  42. 42.
    Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal antiinflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990; 264: 41–7PubMedCrossRefGoogle Scholar
  43. 43.
    Maetzel A, Bosi Ferraz M, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arth Rheum 1998; 41: 16–25CrossRefGoogle Scholar
  44. 44.
    Gabriel SE, Campion ME, O’Fallon WM. Patient preferences for nonsteroidal antiinflammatory drug-related gastrointestinal complications and their prophylaxis. J Rheum 1993; 20: 258–61Google Scholar
  45. 45.
    Johnson RE, Hornbrook MC, Hooker RS, et al. Analysis of the costs of NSAID-associated gastropathy: experience in a US health maintenance organization. Pharmacoeconomics 1997; 12 (1): 76–88PubMedCrossRefGoogle Scholar
  46. 46.
    Kong SX, Hatoum HT, Zhao SZ, et al. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am J Managed Care 1998; 4: 399–409Google Scholar
  47. 47.
    Curtis SP, Mukhopadhyay S, Ramey D, et al. Cardiovascular safety summary associated with the etoricoxib development program. Arthritis Rheum 2003; 48: S35–750CrossRefGoogle Scholar
  48. 48.
    Revicki DA. Relationship between health utility and psychometric health status measures. Med Care 1992; 30: MS274–82CrossRefGoogle Scholar
  49. 49.
    Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732–9PubMedCrossRefGoogle Scholar
  50. 50.
    Nichol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 343–51PubMedGoogle Scholar
  51. 51.
    Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon- alpha2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664–75PubMedGoogle Scholar
  52. 52.
    Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11 (14): 1–160, iii-ivGoogle Scholar
  53. 53.
    Clarke P, Gray A, Legood R, et al. The impact of diabetesrelated complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20: 442–50PubMedCrossRefGoogle Scholar
  54. 54.
    Mehta DK, editor. British national formulary 54: September 2007. London: BMJ Publishing Group and RPS Publishing, 2007Google Scholar
  55. 55.
    McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007; 11 (28): 1–158Google Scholar
  56. 56.
    NHS Trust and PCT combined reference cost, 2005 [online]. Available from URL: http://www.dh.gov.uk [Accessed 2006 Oct 1]
  57. 57.
    Curtis L, Netten A. Unit costs of health and social care 2006. Canterbury: Personal Social Services Research Unit, University of Kent, 2006 [online]. Available from URL: http://www.pssru.ac.uk/pdf/uc/uc2006/uc2006.pdf [Accessed 2007 Apr 1]Google Scholar
  58. 58.
    Government Actuary’s Department (GAD). Interim life tables 20032005, UK [online]. Available from URL: http://www.statistics.gov.uk/StatBase/Product.asp?vlnk=14459&Pos=&ColRank=1&Rank=422 [Accessed 2007 Jun 1]
  59. 59.
    Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85: 169–82PubMedCrossRefGoogle Scholar
  60. 60.
    Gilks WR, Richardson S, Spiegelhalter DJ. Interdisciplinary statistics. In: Gilks WR, Richardson S, Spiegelhalter DJ, editors. Markov chain Monte Carlo in practice. London: Chapman and Hall, 1996Google Scholar
  61. 61.
    Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty: when is there sufficient evidence? Value Health 2005; 8: 433–46PubMedCrossRefGoogle Scholar
  62. 62.
    Boonen A, Chorus A, Miedema H, et al. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001; 60: 353–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Jeroen P. Jansen
    • 1
    Email author
  • Sabine Gaugris
    • 2
  • Ernest H. Choy
    • 3
  • Andrew Ostor
    • 4
  • Julian T. Nash
    • 5
  • Wiro Stam
    • 6
  1. 1.Mapi ValuesBostonUSA
  2. 2.Outcome Research, Merck & Co., Inc.Whitehouse StationUSA
  3. 3.Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of RheumatologyGKT School of Medicine, King’s College HospitalLondonUK
  4. 4.Department of RheumatologyAddenbrooke’s HospitalCambridgeUK
  5. 5.Department of Rheumatology, Royal National Orthopaedic HospitalStanmore HospitalStanmoreUK
  6. 6.Mapi ValuesHoutenthe Netherlands

Personalised recommendations